AF
DYN icon

Amalgamated Financial’s Dyne Therapeutics DYN Stock Holding History

Amalgamated Financial’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$35K Buy
+3,631
New +$30.9K ﹤0.01% 2566

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amalgamated Financial's DYN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Dyne Therapeutics (DYN) in Q1 2022: 3,631 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #2566 among its holdings.

94 funds tracked by Wall St. Rank hold DYN as of Q1 2022.

  • Amalgamated Financial held 3,631 shares of Dyne Therapeutics worth $35K as of Q1 2022.
  • Dyne Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Dyne Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2566 holding.
  • 94 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.